Search results
Adopted in 2011 during the U.S. APEC host year and recognized by APEC Leaders and Ministers, the APEC Mexico City Principles serve as the world’s only voluntary guidance for ethical business conduct in the biopharmaceutical sector with government and multi-stakeholder recognition.
The Mexico City Principles . For Voluntary Codes of Business Ethics in the Biopharmaceutical Sector . st interests of patients. For relationships with healthcare professionals and other stakeholders to meet this standard, companies in the biopharmaceutical sector1 (“Companies”) should be guided.
Adopted in 2011 during the U.S. APEC host year and recognized by APEC Leaders and Ministers, the APEC Mexico City Principles serve as the world’s only voluntary guidance for ethical business conduct in the biopharmaceutical sector with government and multi-stakeholder recognition.
“The Mexico City Principles for Voluntary Codes of Business Ethics in the Biopharmaceutical Sector” (Annex 1) shall be implemented pursuant to the provision of R.A. No. 9711, also known as the “FDA Act of 2009”, in Section 4.0., which mandates FDA to prescribe standards, guidelines, and regulations with respect to information ...
To avoid these unnecessary impediments to the growth of the Biopharmaceutical Sector, The Mexico City Principles was created with the aim to: significantly reduce ethics compliance costs for SMEs by providing greater clarity and a collective understanding of what constitutes appropriate interactions with healthcare professionals to increase the ...
The Mexico City Principles. For Voluntary Codes of Business Ethics in the Biopharmaceutical Sector. Ethical interactions help ensure that medical decisions are made in the best interests of patients.
For relationships with healthcare professionals and other stakeholders to meet this standard, companies in the biopharmaceutical sector 1 (“Companies”) should be guided by these six principles: Healthcare and Patient Focus means everything we do is intended to benefit patients.
